Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846182 · ClinicalTrials.gov registry record · Phase 2
Research Examining Gulf War Illness in Our Nations Service Members
A Phase 2 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT01846182: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT01846182 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 112 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01846182, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive. GWI refers to a complex of symptoms that typically include widespread chronic pain, persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep disturbances and unexplained fatigue. These symptoms are similar to that of fibromyalgia syndrome (FMS), another multi-symptom condition. Whereas, effective treatments for GWI have yet to be found, the FDA has approved duloxetine and pregabalin for the treatment of FMS. The lack of progress in finding effective treatments for GWI, and the similarities between GWI and FMS, provides a rationale for determining if these medications can provide relief to Veterans who suffer from GWI. This randomized controlled trial will test the efficacy of Duloxetine and Pregabalin for treating Gulf War Veterans who suffer from GWI.
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-06-24 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846182
The ClinicalTrials.gov registry entry for NCT01846182 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01846182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01846182 about?
NCT01846182 is a clinical study titled "Research Examining Gulf War Illness in Our Nations Service Members". At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive. GWI refers to a complex of symptoms that typically include widespread chronic pain, persistent headache, memory an...
What is the current status of trial NCT01846182?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2015-06-24. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT01846182?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT01846182?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.